Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05947838 · ClinicalTrials.gov registry record · NA
A Prospective Feasibility Study Using ctDNA to Tailor Neoadjuvant Chemotherapy for Patients With Colorectal or Appendiceal Adenocarcinoma
A NA study of Colorectal and Appendiceal Adenocarcinoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT05947838 is a NA study of Colorectal and Appendiceal Adenocarcinoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 48 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05947838, a NA study of Colorectal and Appendiceal Adenocarcinoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if circulating tumor DNA (ctDNA) testing before cytoreductive surgery (CRS) with or without heated intraperitoneal chemotherapy (HIPEC) can show if patients have a low or high risk of the disease returning and help doctors decide if less or more intense chemotherapy is needed as treatment before surgery. ctDNA testing measures the amount of tumor DNA (genetic information) in the blood.
Conditions Studied
Interventions
- PROCEDURE Circulating tumoral DNA directed neoadjuvant therapy arm
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2023-12-04 |
| Est. Completion | 2026-04-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05947838
The ClinicalTrials.gov registry entry for NCT05947838 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Colorectal appearing as the primary indexed condition, and to 1 intervention - of which Circulating tumoral DNA directed neoadjuvant therapy arm is the first listed.
NCT05947838 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05947838 about?
NCT05947838 is a clinical study titled "A Prospective Feasibility Study Using ctDNA to Tailor Neoadjuvant Chemotherapy for Patients With Colorectal or Appendiceal Adenocarcinoma". To learn if circulating tumor DNA (ctDNA) testing before cytoreductive surgery (CRS) with or without heated intraperitoneal chemotherapy (HIPEC) can show if patients have a low or high risk of the disease returning and help doctors decide if less or more intense chemotherapy is needed as treatment b...
What is the current status of trial NCT05947838?
This trial is currently recruiting. It is a NA study. The enrollment target is 48 participants. The study started on 2023-12-04. Estimated completion is 2026-04-30.
What conditions does trial NCT05947838 study?
This clinical trial studies the following conditions: Colorectal, Appendiceal Adenocarcinoma.
What interventions are being tested in trial NCT05947838?
The interventions under investigation include: Circulating tumoral DNA directed neoadjuvant therapy arm (PROCEDURE).
Who is sponsoring clinical trial NCT05947838?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05947838 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.